ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: Eur J Cardiothorac Surg
Author(s): Andreas Holzamer, Emanuel Sitka, Christian Hengstenberg, Christof Schmid, Kurt Debl, Lars Maier, Daniele Camboni, Oliver Husser, and Michael Hilker

Prediction of the implantation plane in transcatheter aortic valve implantation using a multislice computed tomography-based method is evaluated in 244 patients. The results reveal large interindividual differences

Source: Eur J Cardiothorac Surg
Author(s): Miguel Sousa-Uva, Stuart J. Head, Matthias Thielmann, Giuseppe Cardillo, Umberto Benedetto, Martin Czerny, Joel Dunning, Manuel Castella, Tomas Gudbjartsson, Neil Howell, Mark Hazekamp, Philippe Kolh, Friedhelm Beyersdorf, Domenico Pagano, and A. Pieter Kappetein

How to develop the perfect clinical guideline: Instructions by the European Association for Cardio-Thoracic Surgery (EACTS).

Source: New England Journal of Medicine
Author(s): Steven P. Sedlis, Pamela M. Hartigan, Koon K. Teo, David J. Maron, John A. Spertus, G.B. John Mancini, William Kostuk, Bernard R. Chaitman, Daniel Berman, Jeffrey D. Lorin, Marcin Dada, William S. Weintraub, and William E. Boden for the COURAGE Trial Investigators

The authors report on the extended follow-up of Courage Trial patients for up to 15 years.  In this trial, patients with chronic stable angina were randomized to medical therapy alone versus PCI plus medical therapy.  At extended follow-up, there was no difference in overall survival between the two treatment strategies.

Source: Annals of Thoracic Surgery
Author(s): Stephanie M. Fuller, Xia He, Jeffrey P. Jacobs, Sara K. Pasquali, J. William Gaynor, Christopher E. Mascio, Kevin D. Hill, Marshall L. Jacobs, Yuli Y. Kim

Using the STS Database, a mortality risk score was developed for adult patients undergoing congenital heart surgery.  Procedure-specific outcomes differed by age category.  The age-specific mortality risk score was more accurate than a score for all age categories (81% vs 78%). 

Source: Annals of Thoracic Surgery
Author(s): Pamela Samson, Aalok Patel, Traves D. Crabtree, Daniel Morgensztern, Cliff G. Robinson, Graham A. Colditz, Saiama Waqar, Daniel Kreisel, A. Sasha Krupnick, G. Alexander Patterson, Stephen Broderick, Bryan F. Meyers, Varun Puri

The relationship to institution type and survival after multimodality therapy for IIIA NSCLC was investigated using the NCDB (National Cancer Database).  Academic medical centers had a higher incidence of induction therapy, lower postoperative mortality, and improved overall survival. 

Source: Annals of Thoracic Surgery
Author(s): Michelle C. Ellis, Theron A. Paugh, Timothy A. Dickinson, John Fuller, Jeffrey Chores, Gaetano Paone, Michael Heung, Karsten Fliegner, Andrew L. Pruitt, Himanshu J. Patel, Min Zhang, Richard L. Prager, Donald S. Likosky, for the PERForm Registry and the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative

Data from a large multicenter registry were evaluated to determine whether there is a sex difference in susceptibility to acute kidney injury after CBP related to nadir hematocrit levels.  Based on a 21% hematocrit threshold, 9.5% of men and 31.9% of women were affected.  Rates of AKI were similar between the sexes.  There was a strong interaction betwen sex and nadir Hct level; men were significantly more susceptible to AKI related to nadir Hct.

Source: Annals of Thoracic Surgery
Author(s): Jonathan M. Philpott, Christian W. Zemlin, James L. Cox, Mack Stirling, Michael Mack, Robert L. Hooker, Allen Morris, David A. Heimansohn, James Longoria, Divyakant B. Gandhi, Patrick M. McCarthy

The report of FDA-mandated prospective evaluation of outcomes after Cox Maze-IV for atrial fibrillation during cardiac surgery for other problems.  It utilized the Synergy ablation system and focused on absence of AF off antiarrhythmics at 6 months and the absence of major adverse events at 30 days.  76% were AF free, and 9.1% experienced major complications.  Results were comparable to the cut-and-sew technique of the Cox Maze-III procedure.

Source: Annals of Thoracic Surgery
Author(s): Alexander A. Brescia, Stephen R. Broderick, Traves D. Crabtree, Varun Puri, Joannes F. Musick, Jennifer M. Bell, Daniel Kreisel, A. Sasha Krupnick, G. Alexander Patterson, and Bryan F. Meyers

The goal of this study was to detemine whether adjuvant chemotherapy leads to a survival benefit in patients with positive LNs who have undergone induction chemoradiation therapy followed by esophagectomy. This is a retrospective study of 764 patients undergoing esophagectomy at a single institution from 2000-2013. There were 212 patients with postive LNs on the final pathology report and 101 of these had undergone induction chemoradiation therapy. Of those 101, 45 received adjuvant chemotherapy and 56 did not. There was no difference in two-year freedom from recurrence between the two groups, but patients who did not receive adjuvant had earlier recurrence (6.2 versus 9.4 months). For those who received adjuvant therapy, 5-year survival was significantly longer at 41% (versus 25%). When patients who died within the first 90 days were excluded (1 in the adjuvant group and 5 in the no adjuvant group) the 5-year survival was 42% (adjuvant group) versus 27% (no adjuvant group), but was no longer statistically significant. The authors stated that the survival difference between the two groups may be partially due to sicker patients in the no adjuvant group. The 5-year survival for patients with <=3 (+) LNs was 37% versus 17% for those with >=4 (+) LNs. Independent predictors of survival were age, total number of (+) LNs resected, and pathologic T stage. 

 

Source: New England Journal of Medicine
Author(s): Daniel Goldstein, Alan J. Moskowitz, Annetine C. Gelijns, Gorav Ailawadi, Michael K. Parides, Louis P. Perrault, Judy W. Hung, Pierre Voisine, Francois Dagenais, A. Marc Gillinov, Vinod Thourani, Michael Argenziano, James S. Gammie, Michael Mack, Philippe Demers, Pavan Atluri, Eric A. Rose, Karen O’Sullivan, Deborah L. Williams, Emilia Bagiella, Robert E. Michler, Richard D. Weisel, Marissa A. Miller, Nancy L. Geller, Wendy C. Taddei-Peters, Peter K. Smith, Ellen Moquete, Jessica R. Overbey, Irving L. Kron, Patrick T. O’Gara, and Michael A. Acker for the CTSN

2 year outcomes of a randomized trial of MV repair vs MV replacement for severe ischemic MR are reported.  LVESVI was similar between the two groups.  Recurrent moderate or severe MR was higher in the repair group (59% vs 4%).   The repair group suffered higher rates of heart failure and hospital readmission.  Mortality rates were not different.

Source: New England Journal of Medicine
Author(s): Dwight Reynolds, Gabor Z. Duray, Razali Omar, Kyoko Soejima, Petr Neuzil, Shu Zhang, Calambur Narasimhan, Clemens Steinwender, Josep Brugada, Michael Lloyd, Paul R. Roberts, Venkata Sagi, John Hummel, Maria Grazia Bongiorni, Reinoud E. Knops, Christopher R. Ellis, Charles C. Gornick, Matthew A. Bernabei, Verla Laager, Kurt Stromberg, Eric R. Williams, J. Harrison Hudnall, and Philippe Ritter for the Micra Transcatheter Pacing Study Group

Results of a multicenter trial of a leadless transcatheter pacing system were reviewed in 300 pts at 6 mos.  Implantation was successful in 99%.  Safety was assessed as freedom from system-related or procedure related complications, and was 96%.  Efficacy was assessed as stable pacing capture at low voltage and was 98%.  25 pts suffered major complications, which is less than for typical systems with leads.

Pages